More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.
In light of stocks’ strong performance this past year, there is no lack of exchange-traded funds that posted impressive gains in 2019. In order to identify the best ETFs of 2019, the author of today’s article screened for ETFs that were up at least 50% this year and eliminated leveraged funds. That left just 17 ETFs. For the top five non-leveraged ETFs of 2019 – which span metals, solar, biotech and more – CLICK HERE.
With approximately 100 new biotech companies having begun trading on the Nasdaq exchange since the beginning of last year alone, the author of today’s article observes that “There are so many new biotech stocks hitting the market that plenty of gems slip through the cracks unnoticed” – and he goes on to highlight two of them. For these two under-the-radar biotechs – one of which has developed a potential new treatment for depression while the other “is taking advantage of gravity to develop a blindness prevention drug that lasts longer than the competition” – CLICK HERE.
Low-priced stocks offer smaller investors the chance to not only make a tidy profit (as these stocks can provide the largest short-term gains), but also to acquire a higher share count than they would be able to of large and mega-cap stocks. Today’s article highlights five low-priced (trading under $10) biotech stocks that analysts see as having solid upside potential. For these five biotechs – including two potential takeover targets – that may be especially appealing to more aggressive traders, CLICK HERE.
Biotech investors may be missing out on some very lucrative drugs and therapies. As today’s article notes, while “It is common for large-cap biotech investments…to feature exposure to companies working on treatments for well-known diseases…the growing unmet medical needs universe is going, well, mostly unmet by traditional biotech investments.” Case in point: Non-alcoholic steatohepatitis (NASH) – a potentially fatal liver disease affecting upwards of 16 million Americans and for which there is currently no approved drug therapy. So how can biotech investors access the opportunity presented by NASH and other unmet medical needs? CLICK HERE.
While most stocks currently receiving new Buy or Outperform analyst ratings have upside potential of 8% to 10%, the author of today’s article reminds the reader that “There is another type of Buy rating that is far more speculative, one in which the projected upside can be 50%, 100% or exponentially higher.” He proceeds to highlight five biotech stocks that currently fall into this category – with upside potential ranging from 100% to 400%. For these five biotechs – as well as a couple of runners-up with under-100% (but still high) upside potential – CLICK HERE.
With market volatility – and investor anxiety – back in a big way, the hunt for safe investments is on for many. However, the author of today’s article notes that some traditional safe investment niches – such as consumer stocks and utilities – are not necessarily looking all that attractive. As such, he proceeds to identify one possible safe investment niche to consider: biotech. For more – including what the author sees as “the key to success in this realm” and how to manage risk in this sector – CLICK HERE.
The biotech highlighted in today’s article is the kind of stock that the author would normally advise investors to stay away from. In this case, however, he acknowledges that “this company could be worth quite a lot in the future, if it plays its cards right.” He proceeds to detail the company’s most interesting product – an anti-aging product that he believes has the potential to take it from micro-cap to industry leader (and which is drawing in a number of wealthy investors). For more, CLICK HERE
The biotech sector has been weak of late – and as a result now may be the time to get in. Today’s article looks at some of the factors that lie behind the sector’s current performance – including the delay in getting tax reform passed and the “biotech buyout frenzy” that, despite expectations, failed to come to pass this year – and highlights six biotech stocks that may be good candidates for riding a biotech rebound. For more, CLICK HERE.
He is worried about the reality of more and more people living longer and longer lives (and how they will afford it). He believes the massive influx into index funds is a “serious error” and that the collapse of index funds is “only a question of when.” He sees stock picking as “a dying art” and stock (or fund) picking as a necessity. And he has some advice for investors right now – hoard cash, buy gold and sterling, and invest in this type of stock. For renowned British investor Jim Mellon’s take on the current investing environment, CLICK HERE.